Biomea Fusion, Inc.

Equities

BMEA

US09077A1060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
10.65 ^USD	-6.91%		-13.77%	-26.65%

02/05	Biomea Fusion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03/04	North American Morning Briefing : Powell Awaited -2-	DJ

Biomea Fusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 29, 2024 at 01:36 am IST

Biomea Fusion, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 117.26 million compared to USD 81.83 million a year ago. Basic loss per share from continuing operations was USD 3.44 compared to USD 2.8 a year ago.

Latest news about Biomea Fusion, Inc.

Biomea Fusion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
North American Morning Briefing : Powell Awaited -2-	03/04	DJ
Biomea Fusion Shares Decline Following JPMorgan Downgrade	03/04	MT
JPMorgan Downgrades Biomea Fusion to Neutral From Overweight, Adjusts Price Target to $14 From $51	02/04	MT
Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)	01/04	CI
Biomea Fusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
North American Morning Briefing : Tech in Focus on -2-	25/03	DJ
Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219?s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function	06/03	CI
Truist Securities Starts Biomea Fusion With Buy Rating, $55 Price Target	06/02	MT
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219	08/01	CI
Biomea Fusion, Inc. Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts	10/12	CI
Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes	08/12	CI
Biomea Fusion Says Long-Term Data Show Improved Glycemic Control in Phase 2 Trial of BMF-219 to Treat Diabetes	08/12	MT
Biomea Fusion's Ongoing Phase 2 Study of BMF-219 Shows Glycated Hemoglobin Reductions in Patients With Type 2 Diabetes	07/12	MT
Biomea Fusion Receives Health Canada Clearance for Phase 2 Trial of BMF-219 in Type 1 Diabetes	05/12	MT
Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application for BMF-219 in Type 1 Diabetes	05/12	CI
Biomea Fusion Surges Nearly 20% Premarket Wednesday	29/11	MT
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease	09/11	CI
Biomea Fusion Announces Two Poster Presentations At Upcoming Ash Annual Meeting 2023	02/11	CI
Biomea Fusion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	31/23/31	CI
Biomea Fusion, Inc. Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)	17/23/17	CI
Biomea Fusion Investigational New Drug Application for Diabetes Candidate Approved by FDA	05/23/05	MT
Biomea Fusion Gets FDA, Health Canada Clearance for Expansion Groups in Mid-Stage Diabetes Study	28/23/28	MT
Biomea Fusion Announces Fda and Health Canada Clearance of the Expansion Cohorts of the Ongoing Covvalent-111 Phase Ii Study	28/23/28	CI
Biomea Fusion Names Juan Pablo Frias as Chief Medical Officer, Steve Morris to Become Chief Development Officer	31/23/31	MT

Chart Biomea Fusion, Inc.

Duration

Period

More charts

Company Profile

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).

Sector

Biotechnology & Medical Research

Calendar

13/05/2024 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.65 USD

Average target price

49.5 USD

Spread / Average Target

+364.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOMEA FUSION, INC.	-26.65%	383M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research